Bioethicists Concerned over Japan’s Chimera Embryo Regulations

Many researchers see the move to relax the rules as a welcome change, yet some are worried the revisions don’t take public concerns enough into consideration.

Written byKatarina Zimmer
| 5 min read
japan flag chimera animal research

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: © ISTOCK.COM, BLEW_I

Japanese regulators have effectively given the green light to research involving human-animal chimera embryos, which are created by implanting human pluripotent stem cells into animals in early development. The revised guidelines, issued in early March, lift a previous requirement to terminate such embryos after 14 days.

The revisions now pave the way for Japanese scientists to study how to grow human organs in animals as an alternative to organ transplantation, and to produce better models to study human development and disease.

However, they also raise some ethical concerns, as a group of Japanese bioethicists at the Kyoto University note in a letter published today (April 4) in Cell Stem Cell. For instance, the guidelines would allow researchers to create chimeras with human cells populating animal brains—something that concerns the Japanese public. They also don’t explicitly prohibit chimera embryos made from human and nonhuman primate cells, which ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies